A BELLDEGRUN, DE WEBB, HA AUSTIN III … - Annals of internal medicine, 1987 - Am Coll Physicians Adoptive transfer of autologous lymphokine-activated killer cells in conjunction
with recombinant interleukin-2 in patients with advanced cancer has produced
significant regression of metastatic disease in selected patients. We ... Cited by 123 - Related articles - All 3 versions
SC Textor, K Margolin, D Blayney, J Carlson, … - The American journal of medicine, 1987 - cat.inist.fr Renal, volume, and hormonal changes during therapeutic administration of
recombinant interleukin-2 in man. SC TEXTOR, K MARGOLIN, D ... Cited by 47 - Related articles - All 3 versions
- ►ascopubs.org [PDF] GA Kozeny, JD Nicolas, S Creekmore, L … - Journal of Clinical Oncology, 1988 - jco.ascopubs.org From the Sections of HematologylOncology and Nephrology, Department of Medicine,
Loyola University Medical Center, Maywood, IL. Submitted September 14, 1987;
accepted January 20, 1988. Portions of the data were presented at the Tenth ... Cited by 37 - Related articles - All 5 versions
DE Webb, HA Austin 3rd, A Belldegrun, E … - Clinical nephrology, 1988 - ncbi.nlm.nih.gov The systemic administration of recombinant interleukin-2 (IL-2) either alone or
in combination with lymphokine activated killer cells is a new approach to the
immunotherapy of metastatic cancer in man. Renal toxicity is often a dose- ... Cited by 38 - Related articles - All 2 versions
- ►hematologylibrary.org [PDF] SE Ettinghausen, JG Moore, DE White, L … - Blood, 1987 - bloodjournal.hematologylibrary.org . Hematology; all rights reserved Copyright 2007 by The American Society of DC
20036. by the American Society of Hematology, 1900 M St, NW, Suite 200,
Washington Blood (print ISSN 0006-4971, online ISSN 1528-0020), is ... Cited by 107 - Related articles - All 5 versions
- ►jcojournal.org [PDF] CL Shalmi, JP Dutcher, DA Feinfeld, KJ Chun … - Journal of Clinical Oncology, 1990 - jcojournal.org Adoptive immunotherapy with interleukin-2 (IL-2) and lymphokine-activated killer
(LAK) cells has been effec- tive in treating some advanced malignancies in ani-
mals and humans. One complication of this treatment is a reversible, ... Cited by 29 - Related articles - All 6 versions
NP Christiansen, KM Skubitz, K Nath, A … - The American journal of medicine, 1988 - Elsevier Adoptive immunotherapy with recombinant interleukin-2 has been complicated by
significant nephrotoxicity of uncertain etiology. Creatinine clearance,
effective renal plasma flow, plasma renin activity, aldosterone levels, and ... Cited by 27 - Related articles - All 5 versions
MT Lotze, YL Matory, AA Rayner, SE … - Cancer, 1986 - ncbi.nlm.nih.gov Interleukin-2 (IL-2) is a 15,000 dalton glycoprotein produced naturally by human
T-cells during an immune response. IL-2 has been demonstrated to have
substantial activity alone or in combination with the adoptive transfer of ... Cited by 226 - Related articles - All 2 versions
- ►ascopubs.org [PDF] RE Lee, MT Lotze, JM Skibber, E Tucker, RO … - Journal of Clinical Oncology, 1989 - jco.ascopubs.org From the Surgery Branch, National Cancer Institute; the Critical Care and
Nuclear Medicine Departments, Clinical Center, and the Cardiology Branch,
National Heart, Lung and Blood Institute, National Institutes of Health, ... Cited by 159 - Related articles - All 6 versions
A Belldegrun, DE Webb, HA Austin 3rd, SM … - The Journal of urology, 1989 - ncbi.nlm.nih.gov 1: J Urol. 1989 Mar;141(3):499-503. Renal toxicity of interleukin-2
administration in patients with metastatic renal cell cancer ... Cited by 26 - Related articles - All 3 versions
